Azitra AZTR
NYSE AZTR
$0.13 +0.01 (+4.81%)
At close: Aug 21, 2026 · 4:00 PM EDT

Azitra (AZTR) Liabilities and Shareholders Equity (2022 - 2026)

Azitra's (AZTR) quarterly Liabilities and Shareholders Equity came in at $12.1 million in Q1 2026, up 105.26% YoY from $5.9 million in Q1 2025, and up 141.31% on a QoQ basis from $5.0 million in Q4 2025.

Azitra (AZTR) Liabilities and Shareholders Equity (2022 - 2026) Analysis & Trends

Azitra (AZTR) has 5 years of Liabilities and Shareholders Equity data on file, last reported at $12.1 million in Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 105.26% year-over-year to $12.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.4 million (down 5.64% YoY) and the FY2025 annual result came in at $5.0 million, down 31.71% from the prior year.
  • Liabilities and Shareholders Equity climbed to $12.1 million in Q1 2026, from $5.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $12.1 million in Q1 2026 to a low of $3.9 million in Q2 2024.
  • A 5-year average of $6.8 million and a median of $6.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity slumped 60.5% — and 2026, when it surged 105.26%.
  • Tracing AZTR's Liabilities and Shareholders Equity over 5 years: stood at $7.2 million in 2022, then dropped by 28.63% to $5.1 million in 2023, then soared by 43.85% to $7.4 million in 2024, then sank by 31.71% to $5.0 million in 2025, then jumped by 141.31% to $12.1 million in 2026.
  • The last three Liabilities and Shareholders Equity figures came in at $12.1 million (Q1 2026), $5.0 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 10.96 Bn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 9.18 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 5.56 Bn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 25.60 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 2.10 Bn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 19.82 Bn
10 Azitra 2.53 Mn 2.53 Mn - 8.92 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 8.92 Mn
Mar 31, 2026 12.13 Mn
Dec 31, 2025 5.03 Mn
Sep 30, 2025 4.30 Mn
Jun 30, 2025 3.96 Mn
Mar 31, 2025 5.91 Mn
Dec 31, 2024 7.36 Mn
Sep 30, 2024 9.78 Mn
Jun 30, 2024 3.88 Mn
Mar 31, 2024 6.07 Mn
Dec 31, 2023 5.12 Mn
Sep 30, 2023 7.49 Mn
Jun 30, 2023 9.83 Mn
Dec 31, 2022 7.17 Mn